Anti-inflammatory actions of the natural plant product, Honokiol
Anti-inflammatory actions of the natural plant product, Honokiol
批准号:
7664529
负责人:
GAIL A. BISHOP
金额:
$22.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-08-01 至 2011-01-31
关键词:
Adverse effectsAffectAnti-Inflammatory AgentsAnti-inflammatoryAnxiety DisordersAsiansAutoimmune DiseasesB-LymphocytesBiologicalBiological FactorsCancer cell lineCell DeathCellsChronicCollagen ArthritisControlled StudyDataDendritic CellsDiseaseDisease ProgressionDisease modelDoseGABA ReceptorGastrointestinal DiseasesGrowthHumanImmunologic ReceptorsIn VitroInflammationInflammatoryInterleukin-6LMP1LeftMagnoliaMedicineMusNervous system structurePlant ExtractsPlant RootsPlantsPlayProductionPropertyPublishingReportingResearchRheumatoid ArthritisRoleRouteSignal PathwaySignal TransductionTNFRSF5 geneTestingTherapeutic UsesTimeToxic effectTraditional MedicineWorkcytokineeffective therapygastrointestinalhonokiolin vivomacrophagemouse modelpublic health relevancereceptorsingle moleculestemtumor
中文摘要
描述(由申请人提供):檀香木(HNK)是木兰属植物的叶和根茎的天然提取物,长期以来一直用于亚洲传统医学,治疗血栓形成和胃肠道疾病。为了确定HNK是否具有抗炎特性,我们在炎症性类风湿性关节炎(RA)的小鼠模型中测试了其作用。我们的初步研究表明,体内炎症和疾病进展以及体外促炎细胞因子的产生和细胞活化均受到显著抑制,而没有增加细胞死亡或体内毒性。这些初步研究结果表明,HNK在治疗慢性炎症性疾病如RA方面有希望,这影响了大量的人。HNK还通过CD40抑制信号传导,CD40是一种在RA中发挥作用的免疫受体,以及EBV编码的称为LMP1的CD40模拟物,其与加重自身免疫性疾病有关。由于HNK具有多种抗炎作用,它可能比针对单一分子的治疗更有效。它在传统医学中的长期使用也表明它可以有效而没有危险的副作用。该探索性项目将测试HNK在RA小鼠模型中具有有效抗炎特性的假设,并且其作用将通过与GABA受体相互作用来发挥,以减少促炎细胞因子的产生。第一个具体目标将集中在优化小鼠RA疾病模型中的抗炎作用,第二个目标将检查HNK的作用机制。
公共卫生相关性:该项目研究一种名为Honokaline(HNK)的天然植物产品,该产品是从木兰属植物中提取的,多年来一直被用作传统的亚洲药物,没有明显的毒副作用。在人类类风湿性关节炎(RA)的小鼠模型中进行对照研究,我们的初步工作表明HNK可以抑制炎症和疾病的进展。有趣的是,初步数据表明HNK通过神经系统的一种受体向细胞传递信号。目前的项目旨在建立在这些研究的基础上,以确定使用HNK作为慢性炎症性疾病治疗的最佳方法,并更好地了解HNK如何发挥其抗炎作用。
英文摘要
DESCRIPTION (provided by applicant): Honokiol (HNK) is a natural extract of the leaves and root stems of the Magnolia plant that has long been used in traditional Asian medicine to treat thrombotic and gastrointestinal disorders. To determine if HNK has anti-inflammatory properties, we tested its effects in a mouse model of inflammatory rheumatoid arthritis (RA). Our initial studies show that both in vivo inflammation and disease progression and in vitro pro-inflammatory cytokine production and cellular activation were markedly inhibited, without increased cell death or in vivo toxicity. These preliminary findings suggest that HNK has promise in the treatment of chronic inflammatory diseases such as RA, which affects a large number of people. HNK also inhibited signaling via CD40, an immune receptor that has been implicated as playing a role in RA, as well as an EBV-encoded CD40 mimic called LMP1, that has been implicated in exacerbating autoimmune disease. Because HNK has multiple anti-inflammatory actions, it could prove more effective than treatments targeting a single molecule. Its long prior use in traditional medicine also suggests that it can be effective without dangerous side effects. This exploratory project will test the hypothesis that HNK will have effective anti-inflammatory properties in a mouse model of RA, and that its action will be exerted via interaction with GABA receptors to decrease production of pro-inflammatory cytokines. The first specific Aim will focus on optimizing anti-inflammatory effects in the mouse RA disease model, and the second Aim will examine the mechanism of action of HNK.
PUBLIC HEALTH RELEVANCE: This project studies a natural plant product called Honokiol (HNK), which is extracted from plants of the species Magnolia, and has been used for many years as a traditional Asian medicine, without notable toxic side effects. Using controlled studies in a mouse model of human rheumatoid arthritis (RA), our initial work has shown that HNK can inhibit inflammation and progression of the disease. Interestingly, preliminary data indicate that HNK delivers signals to cells through a type of receptor of the nervous system. The current project seeks to build upon these studies to determine the optimal way to use HNK as a treatment for chronic inflammatory disease, and to better understand how HNK exerts its anti- inflammatory effects.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.4049/jimmunol.1000630
发表时间:
2010-11-01
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
[Munroe ME, Businga TR, Kline JN, Bishop GA]
通讯作者:
Bishop GA
Regulation of B cell signaling in autoimmunity by TRAF3
-
批准号:10272524
-
项目类别:
-
资助金额:$47.58万
-
财政年份:2021
-
负责人:GAIL A. BISHOP
-
依托单位:
Regulation of B cell signaling in autoimmunity by TRAF3
-
批准号:10669670
-
项目类别:
-
资助金额:$44.28万
-
财政年份:2021
-
负责人:GAIL A. BISHOP
-
依托单位:
Regulation of B cell signaling in autoimmunity by TRAF3
-
批准号:10457447
-
项目类别:
-
资助金额:$44.75万
-
财政年份:2021
-
负责人:GAIL A. BISHOP
-
依托单位:
Regulation of B cell signaling in autoimmunity by TRAF3
-
批准号:10533971
-
项目类别:
-
资助金额:$7.78万
-
财政年份:2021
-
负责人:GAIL A. BISHOP
-
依托单位:
Regulation of B cell signaling in autoimmunity by TRAF3
-
批准号:10728904
-
项目类别:
-
资助金额:$7.78万
-
财政年份:2021
-
负责人:GAIL A. BISHOP
-
依托单位:
Loss of TRAF3 in aging B lymphocytes
-
批准号:10116246
-
项目类别:
-
资助金额:$23.18万
-
财政年份:2020
-
负责人:GAIL A. BISHOP
-
依托单位:
BLRD Research Career Scientist Award Application
-
批准号:10514631
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:GAIL A. BISHOP
-
依托单位:
BLRD Research Career Scientist Award Application
-
批准号:10337030
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:GAIL A. BISHOP
-
依托单位:
Molecular regulation of T cell activation signals by TRAF3
-
批准号:9211288
-
项目类别:
-
资助金额:$38.13万
-
财政年份:2016
-
负责人:GAIL A. BISHOP
-
依托单位:
Molecular regulation of T cell activation signals by TRAF3
-
批准号:9075045
-
项目类别:
-
资助金额:$37.97万
-
财政年份:2016
-
负责人:GAIL A. BISHOP
-
依托单位:
Understanding and applying innate and adaptive immune signal interactions
-
批准号:8621977
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:GAIL A. BISHOP
-
依托单位:
Understanding and applying innate and adaptive immune signal interactions
-
批准号:8762437
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:GAIL A. BISHOP
-
依托单位:
Understanding and applying innate and adaptive immune signal interactions
-
批准号:8435794
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:GAIL A. BISHOP
-
依托单位:
Understanding and applying innate and adaptive immune signal interactions
-
批准号:8963452
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2012
-
负责人:GAIL A. BISHOP
-
依托单位:
Regulation of lymphocyte receptor signaling by TRAF interactions
-
批准号:8078514
-
项目类别:
-
资助金额:$37.41万
-
财政年份:2010
-
负责人:GAIL A. BISHOP
-
依托单位:
Anti-inflammatory actions of the natural plant product, Honokiol
-
批准号:7530193
-
项目类别:
-
资助金额:$18.75万
-
财政年份:2008
-
负责人:GAIL A. BISHOP
-
依托单位:
Mechanisms of Alteration of B Lymphocyte Function by LMP1
-
批准号:7646931
-
项目类别:
-
资助金额:$33.54万
-
财政年份:2003
-
负责人:GAIL A. BISHOP
-
依托单位:
B cell signaling by the EBV transforming protein, LMP1
-
批准号:6596452
-
项目类别:
-
资助金额:$33.19万
-
财政年份:2003
-
负责人:GAIL A. BISHOP
-
依托单位:
B cell signaling by the EBV transforming protein, LMP1
-
批准号:7196446
-
项目类别:
-
资助金额:$28.01万
-
财政年份:2003
-
负责人:GAIL A. BISHOP
-
依托单位:
Mechanisms of Alteration of B Lymphocyte Function by LMP1
-
批准号:7779966
-
项目类别:
-
资助金额:$33.38万
-
财政年份:2003
-
负责人:GAIL A. BISHOP
-
依托单位:
海外基金